Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer

Breast cancer is a very frequent type of cancer and much attention is paid to therapy with considerable efforts both in the pharmacological and clinical fields.The present work aims to create a non-linear dynamic model of action of the drug Trastuzumab against HER-2 + breast cancer, mainly considering its action of ADCP (antibody-dependent phagocytosis) killing of cancer cells. The model, while also considering the other therapeutic effects induced by Trastuzumab, shows how the action of this monoclonal antibody in the induction of ADCP through the action of macrophages, is strictly connected to the formation of a multi-complex “Trastuzumab -HER-2 - macrophage” that shows a prolonged action over time, responsible for the increase in the Overall Survivor (OS) parameter reported in various. The model shows the correlation between the various therapeutic effects and the killing action of cancer cells through the variation of the dynamic fluctuation of the representative ”c” parameter.

• Publication year

  2021

• Venue

  Saudi Journal of Biological Sciences

• Publication date

  2021-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.sjbs.2021.08.061PMID 35002400PMCID 8717090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Self organizing maps for the parametric analysis of COVID-19 SEIRS delayed model

  2021cited by this paper
• Delayed Modeling Approach to Forecast the Periodic Behavior of SARS-2

  2021cited by this paper
• Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection

  2020cited by this paper
• Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

  2019cited by this paper
• Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients

  2016cited by this paper
• Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages

  2015cited by this paper
• Stability and boundedness of solutions of nonlinear vector differential equations of third order

  2014cited by this paper
• Stability and bounded of solutions to non-autonomous delay differential equations of third order

  2010cited by this paper
• Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

  2007cited by this paper
• Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

  2006cited by this paper
• Engineered antibody Fc variants with enhanced effector function.

  2006cited by this paper
• HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

  2006cited by this paper
• The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• New approaches to antibody therapy

  2000cited by this paper
• ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• An Efficient Method for Computing Synaptic Conductances Based on a Kinetic Model of Receptor Binding

  1994cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Poly(Epsilon-Lysine) Dendrons Inhibit Proliferation in HER2-Overexpressing SKBR3 Breast Cancer Cells at Levels Higher than the Low-Expressing MDA-MB-231 Phenotype and Independently from the Presentation of HER2 Bioligands in Their Structure

  2024cites this paper
• Redefining Roles: A Paradigm Shift in Tryptophan–Kynurenine Metabolism for Innovative Clinical Applications

  2024cites this paper
• Novel Numerical Method Based on the Analog Equation Method for a Class of Anisotropic Convection-Diffusion Problems

  2022cites this paper
• “AI-MCMC” for the parametric analysis of the hormonal therapy of cancer

  2021cites this paper